|
Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
Posted on: Friday, 11 September 2009, 15:01 CDT
Signum Biosciences Awarded $1.6 Million Grant by the NIH
MONMOUTH JUNCTION, N.J., Sept. 11 /PRNewswire/ -- Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.
In 2008, NIH/NIAID awarded Signum a SBIR Phase I grant to establish this novel class of anti-inflammatories. SBIR Phase II grants enable SBIR Phase I grantees to further develop their technology and prepare it for commercialization. Signum will use the Phase II grant to fund preclinical development of Signum's lead drug candidates for rosacea. Rosacea is a common, chronic cutaneous condition afflicting millions of individuals. FDA approved treatments have yielded mixed results, often leaving patients with significant levels of facial redness. Successful pharmaceutical development of STM anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea redness.
July 12, 2010 Signum Biosciences, Inc. Announces Commercial Launch of Arazine (TM) in Japan
More info
|
